Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
77 hedge funds and large institutions have $145M invested in Concert Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 30 reducing their positions, and 14 closing their positions.
57% more capital invested
Capital invested by funds: $92.4M → $145M (+$53.1M)
4% less funds holding
Funds holding: 80 → 77 (-3)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
20% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 30
54% less call options, than puts
Call options by funds: $174K | Put options by funds: $380K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.36M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.26M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$926K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$435K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.67M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$818K |
| 3 |
Morgan Stanley
New York
|
-$809K |
| 4 |
ISL
Ingalls & Snyder LLC
New York
|
-$469K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$442K |
CNCE Hedge Fund Activity: Q4 2019 in Review
77 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2019, worth a combined $145M — up 57% from $92.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CNCE and 12 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 24 added.
The largest buyer was Bank of America, adding an estimated $2.36M. The largest seller was BlackRock, cutting an estimated $1.67M.
- 77 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2019, down from 80 in Q3 2019.
- Funds reported $145M of Concert Pharmaceuticals, Inc. stock for Q4 2019, up 57% quarter-over-quarter.
- 12 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2019 and 14 closed out, a net change of -2 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2019 was Bank of America, an estimated $2.36M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2019 was BlackRock, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2019.